Mapping the immune System's fight against certain cancers

NCT ID NCT04665388

Recruiting now Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how T cells (a type of immune cell) respond to liver cancer and cancers linked to Epstein-Barr virus (EBV) and human papillomavirus (HPV). About 105 participants will give blood and tissue samples once. Researchers will analyze these samples to identify cancer-specific T cells and their receptors. The goal is to better understand the immune response, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help design better immunotherapies for these cancers by identifying key immune targets.
What could go wrong: This is an observational study, not a treatment trial. It is small (105 participants) and early-stage, so findings may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS-RELATED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus-related tumor hepatocellular carcinoma human papillomavirus-related squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.